Efficacy and safety of rituximab in central nervous system demyelinating disorders
Background: Rituximab, an anti-CD20 monoclonal antibody, has been used worldwide as an off-label therapy in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). Objective: The aim of the present study was to evaluate the efficacy and safety of rituximab in centr...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Schriftenreihe: | Annals of Indian Academy of Neurology |
| Schlagworte: | |
| Online-Zugang: | http://www.annalsofian.org/article.asp?issn=0972-2327;year=2021;volume=24;issue=5;spage=732;epage=739;aulast=Patil |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|